-
Mashup Score: 3
Tocilizumab-aazg (Tyenne; Fresenius Kabi) is the first approved biosimilar to tocilizumab (Actemra; Genentech) as both intravenous and subcutaneous.
Source: www.pharmacytimes.comCategories: General Medicine News, General Journals & SocietTweet
-
Mashup Score: 0Second RSV Vaccine Lands Approval for Older Adults - 11 month(s) ago
Abrysvo approved for adults 60 and up
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
The FDA has approved a second #RSV vaccine for preventing lower respiratory infections in adults 60 and over, @pfizer recently announced. #MedTwitter #FDAApproved https://t.co/ln8i8dWrjE
-
-
Mashup Score: 0Antibody-Drug Conjugate Gets FDA Thumbs Up for Untreated DLBCL - 1 year(s) ago
Adding polatuzumab vedotin to a modified version of R-CHOP significantly improved PFS
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
The FDA approved the antibody-drug conjugate (#ADC) polatuzumab vedotin (#Polivy) plus standard therapy for certain types of untreated diffuse large B-cell lymphoma (#DLBCL), according to a statement from @genentech. #FDAapproved #OncoTwitter #MedTwitter https://t.co/zG8S2hXQGD
-
-
Mashup Score: 0FDA OKs First Therapy for Alpha-Mannosidosis - 1 year(s) ago
Velmanase alfa approved for treating non-CNS manifestations of progressive, inherited disease
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
#FDAapproved ✅ the enzyme replacement therapy velmanase alfa (Lamzede) for alpha-mannosidosis, developer @ChiesiGRD announced on Thursday. https://t.co/TBYoAQfKuI
-
-
Mashup Score: 0FDA Greenlights First Drug for ESR1-Mutated Breast Cancer - 1 year(s) ago
Elacestrant almost doubled PFS versus standard endocrine therapy in advanced ER+/HER2- disease
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
#FDAapproved ✅ #elacestrant (#Orserdu) for the treatment of postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic #breastcancer. https://t.co/QvnGWmAHo4 @dradityabardia #bcsm #OncTwitter
-
-
Mashup Score: 0FDA Greenlights BTK Inhibitor Zanubrutinib for CLL/SLL - 1 year(s) ago
Phase III studies showed the drug’s efficacy, safety in first-line, relapsed/refractory settings
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
#FDAapproved ✅BTK inhibitor zanubrutinib for the treatment of patients w/ CLL or SLL. "We have seen striking data from the Brukinsa development program demonstrating significant & consistent efficacy across CLL patient subtypes." -Jennifer Brown, MD, PhD. https://t.co/Vp6JXZ1uGq
-
-
Mashup Score: 0
Second-line tucatinib plus trastuzumab combo gets accelerated approval in metastatic disease
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
Tucatinib (Tukysa) in combination with trastuzumab (Herceptin) is the first #FDAapproved ✅ treatment for HER2-positive metastatic #colorectalcancer, @SeagenGlobal announced. https://t.co/7ZZZnYTJgC
-
-
Mashup Score: 1Wegovy OK'd for Teens With Obesity - 1 year(s) ago
New indication for popular weight-loss injectable
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
#FDAapproved ✅ injectable #semaglutide 2.4 mg (#Wegovy) for people with #obesity ages 12 and up, @novonordiskus said. This new indication for the GLP-1 receptor agonist marks the first anti-obesity medicine for teens w/ once-weekly dosing: https://t.co/0BTxmTxCtg @MedPageEndo
-
-
Mashup Score: 0
Half of patients achieved complete responses with adenoviral vector-based product
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
#FDAapproved ✅ nadofaragene firadenovec (#Adstiladrin) as the first gene therapy for the treatment of high-risk BCG-unresponsive NMIBC. "[This is] a significant advance in the current treatment landscape." -@SBoorjian https://t.co/FqD43Z4Elu #OncTwitter #MedTwitter
-
-
Mashup Score: 2Adagrasib OK'd for KRAS-Mutant Lung Cancer - 1 year(s) ago
Targeted agent approved as second-line therapy in locally advanced or metastatic disease
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
#FDAApproved ✅ adagrasib (Krazati), an oral targeted agent for treating locally advanced or metastatic non-small cell #lungcancer associated with KRASG12C mutations. https://t.co/KEusjCbSAa @ShirishGadgeel #OncTwitter
-
Tocilizumab-aazg (Tyenne; Fresenius Kabi) is the first approved biosimilar to tocilizumab (Actemra; Genentech) as both intravenous and subcutaneous. #FDA #Approved Read More: https://t.co/DdXf0TtzJb